Glaucoma Treatment and Deprivation: Time-Series Analysis of General Practice Prescribing in England

BACKGROUND:Despite advances in glaucoma management, topical eyedrop treatment has been paramount, with prostaglandin analogues (PGAs) being first-line agents. While late presentation is linked with deprivation, there is no recent research examining associations between deprivation and prescribing within primary care.AIM:To explore PGA prescribing in general practice over a 6-year timeline, assessing for associations with deprivation.DESIGN & SETTING:Analysis of NHS Business Services Authority data for general practice prescribing in England from April 2016-March 2022.METHOD:Glaucoma treatments by GP prescriber were extracted, identifying ~9.11-9.58 million prescriptions/annum. Data were linked to indices of multiple deprivation (IMD) quintiles of GP practices. Crude rates per 1,000 population were calculated using population data from NHS Digital. Time-series analyses facilitated comparison in prescribing nationally and in deprived areas. Autoregressive Integrated Moving Average (ARIMA) modelling facilitated measurement of synchrony between time-series using cross correlation.RESULTS:PGAs and fixed combination eyedrops account for approximately two-thirds of glaucoma-related prescribing. Prescriptions per month increased slightly over a 6-year timeline, but rates per 1,000 of population reduced in 2020-21. PGA prescriptions dispensed in deprived areas is lower than all other quintiles. Cross-correlation analysis indicates a lag of ~12 months between average PGA prescribing nationally versus more deprived areas.CONCLUSION:The rate of PGA prescribing in primary care is substantially lower in deprived versus affluent areas, with delayed uptake of PGAs in more deprived areas of ~12 months. Further research is needed to explore reasons for this discrepancy, permitting strategies to be developed to reduce unwarranted variation.